



H.E. Mrs Saira Afzal Tarar  
Federal Minister of National Health Services, Regulations and Coordination  
Government of Pakistan  
Islamabad  
Pakistan

12 May 2016

**Decision Letter: Request for 2016 Renewal of Gavi support for Pentavalent vaccine**

Your Excellency,


I am writing in relation to Pakistan's request for support to Pentavalent Vaccine for 2016 which was approved by Gavi in October 2015 and communicated to the country through the Decision Letter dated 19 January 2016.

We acknowledge that Pakistan has been procuring its co-financing share of Pentavalent vaccine locally for the past few years and therefore would like to amend the previously shared Decision Letter to reflect this information by amending item 13 in the Decision Letter. Kindly notice the present Decision Letter replaces the one sent earlier, dated 19 January 2016.

I would like to take this opportunity to thank you for your continued commitment to the immunization efforts in Pakistan and encourage you to not hesitate to contact my colleague Dr. Hamidreza Setayesh at [hsetayesh@gavi.org](mailto:hsetayesh@gavi.org) if you have any questions, concerns or would like to have any additional information.

Yours sincerely,

  
Barry Greene  
Managing Director  
Finance & Operations  
The GAVI Alliance

 Hind Khatib-Othman  
Managing Director, Country Programmes

Appendix A-1: Financial and programmatic information for Pentavalent vaccine support

cc: The Minister of Finance

The EPI Manager  
WHO Country Representative  
UNICEF Country Representative  
Regional Working Group  
WHO HQ  
UNICEF Programme Division  
UNICEF Supply Division

**Pakistan support for Pentavalent vaccine**

This decision letter sets out the programme terms of a programme.

<b>1. Country:</b> Pakistan			
<b>2. Grant number:</b> 16-PAK-04a-X			
<b>3. Date of decision letter:</b> 12/05/2016			
<b>4. Date of the partnership framework agreement:</b> 19/05/2015			
<b>5. Programme title:</b> New vaccine support (NVS), Pentavalent Routine			
<b>6. Vaccine type:</b> Pentavalent			
<b>7. Requested product presentation and formulation of vaccine:</b> DTP-HepB-Hib, 1 dose(s) per vial, LIQUID			
<b>8. Programme duration<sup>1</sup>:</b> 2008 - 2016			
<b>9. Programme budget (indicative):</b> This is the amount endorsed by Gavi for the entire duration of the programme (subject to the terms of the partnership framework agreement)			
<b>Programme year</b>	<b>2008-2015</b>	<b>2016</b>	<b>Total</b>
Programme budget	US\$300,608,414 <sup>2</sup>	US\$25,617,000	US\$326,225,414
<b>10. Vaccine introduction grant (in US\$):</b> Not applicable			
<b>11. Indicative annual amounts:</b> This is the amount Gavi has approved to be disbursed for programme year 2016 of implementation (subject to the terms of the partnership framework agreement)			
<b>Type of supplies to be purchased with Gavi funds in each year</b>	<b>2008-2015</b>	<b>2016</b>	
Number of Pentavalent vaccines doses			10,374,100
Number of AD syringes			10,868,100
Number of re-constitution syringes			N/A
Number of safety boxes			119,575
Annual amounts (US\$)	US\$300,608,414	US\$25,617,000	
<b>12. Procurement agency:</b> UNICEF shall be the procurement agency for vaccines purchased with Gavi funding.			
<b>13. Self-procurement:</b> Self-procurement applies to co-financed portion.			

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the consolidated amount for all previous years.

<p><b>14. Co-financing obligations:</b> Reference code: 16-PAK-04a-X-C According to the co-financing policy, the Country falls within the Preparatory Transition phase. Following the approved Country Tailored Approach for Pakistan that allows the alignment of timing of country's co-financing requirements with its fiscal year, Pakistan is required to fulfill the following obligations covering fiscal year 2015/2016 at the latest by 30th of June 2016 and 2016/2017 by 30th of June 2017.</p>		
<b>Type of supplies to be purchased with Country funds in each year</b>	<b>FY 2015/2016</b>	<b>FY 2016/2017</b>
Number of vaccine doses	2,581,900	5,043,600
Number of AD syringes	2,663,000	5,283,700
Number of re-constitution syringes		
Number of safety boxes	29,300	58,125
Value of vaccine doses (US\$)	US\$4,939,031	US\$11,919,432
Total co-financing payments (US\$) (including freight)	US\$5,256,000	US\$12,454,000
<p><b>15. Operational support for campaigns:</b> Not applicable</p>		
<p><b>16. Additional reporting requirements:</b> The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future annual amounts.</p>		
<b>Reports and other information</b>	<b>Due dates</b>	
To prepare for the annual procurement of vaccines, Country shall submit the following information in May of each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2016	
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat in the context of GAMR Internal Appraisal for Support 2016	
<p><b>17. Financial clarifications:</b> Not applicable</p>		
<p><b>18. Other conditions:</b> The country is reminded of its obligations under the PFA in respect of insurance and is requested to provide information to Gavi on the steps it has taken in this regard.</p>		

Signed by,

**FOR:** On behalf of Gavi  
Hind Khatib-Othman  
Managing Director, Country Programmes  
12 May 2016

  
Barry Greene  
Managing Director  
Finance & Operations  
The GAVI Alliance